Trigemina, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Trigemina, Inc. - overview
Established
2006
Location
Mountain View, CA, US
Primary Industry
Pharmaceuticals
About
Trigemina, Inc. develops advanced medical devices and software solutions aimed at enhancing healthcare delivery and improving patient outcomes for clinicians and healthcare providers. Trigemina, Inc. was founded in 2006 and is headquartered in Mountain View, US.
The company focuses on creating innovative healthcare solutions. In June 2013, Trigemina raised USD 4. 5 mn in a Series A funding round led by Aurus. The total amount raised by the company is USD 4.
5 mn, and it has completed 2 deals to date. Trigemina specializes in developing innovative solutions aimed at enhancing the delivery of healthcare and improving patient outcomes. The company's core product offerings include advanced medical devices and software platforms that enable healthcare professionals to monitor and manage patient conditions more effectively. These products are designed to address specific healthcare challenges, such as chronic pain management and real-time health monitoring, providing clinicians with actionable insights.
Trigemina's client base consists of hospitals, clinics, and healthcare providers across various geographical markets, including North America and Europe. The revenue generation model of Trigemina is structured around B2B relationships with healthcare facilities that utilize the company's medical devices and software solutions. Transactions typically occur through direct sales and long-term partnerships, fostering a steady revenue stream as healthcare providers integrate Trigemina's offerings into their operational frameworks. Pricing plans for Trigemina's flagship products are tailored to accommodate the unique needs of healthcare providers, ensuring accessibility while maintaining quality standards.
Trigemina plans to utilize the USD 4. 5 mn raised in June 2013 for further product development and market expansion. The company is working on launching new medical devices and software solutions aimed at addressing additional healthcare challenges. Specific targets for market expansion include penetrating deeper into European markets by 2024.
Current Investors
Aurus
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
trigemina.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.